Vulvovaginal Candidiasis Caused by Non-Albicans Candida (e.g. Candida glabrata) Not Responding to First-Line Antimycotics

Clinical scenario

This protocol addresses vulvovaginal candidiasis in which the causative organism is a non-albicans Candida species — most commonly Candida glabrata — and the infection has not responded to standard doses of first-line antimycotic agents.

What makes this situation distinct

Non-albicans species such as C. glabrata behave differently from Candida albicans and typically require alternative antifungal strategies rather than conventional first-line antimycotics. When usual-dose therapy has not achieved a response, a targeted approach is indicated. Unnecessary antimycotic use should be avoided, and treatment selection should reflect the specific organism.

Treatment approach (overview)

The protocol for this scenario involves agents from a specific antifungal class, reserved for selected cases. The full structured regimen — including which agents apply, the conditions that must be met, and the clinical thresholds — is detailed in the protocol.

Full regimen, eligibility criteria, and sequencing available via the link below →

Instant Access to Structured Evidence-Based Regimens

References

Unnecessary antimycotic therapies should always be avoided, and non-albicans vaginitis should be treated with alternative antifungal agents.

In case of C glabrata vaginitis, local administration of nystatin or ciclopiroxolamine might be considered.

Treatment with echinocandins (eg micafungin) should be limited to cases with massive complaints as VVC is not approved as treatment indication with little evidence.

DOI: 10.1111/myc.13248

View source ↗